Navigation Links
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Date:6/16/2008

Results presented at the 90th annual Endocrine Society meeting show significant improvements among women affected by moderate to severe vaginal

dryness and painful intercourse

ANN ARBOR, Mich, June 16 /PRNewswire/ -- QuatRx Pharmaceuticals today announced detailed primary endpoint results from a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women with symptoms of vulvovaginal atrophy, a common condition associated with menopause. The study successfully met all four co-primary endpoints. Women treated with Ophena(TM) at the 60 mg dose showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels. Results of this Phase 3 clinical trial were presented today in a poster presentation at the 90th annual Endocrine Society meeting in San Francisco.

The decline in estrogen levels in women after menopause is associated with an increase in vaginal pH levels as well as a thinning of the vaginal wall, resulting in bothersome symptoms such as vaginal dryness and painful intercourse. In the Phase 3 Ophena(TM) clinical study, women were asked to identify their most bothersome symptom of vaginal atrophy. The co-primary endpoints were defined as the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal atrophy symptom.

"Vaginal atrophy symptoms in postmenopausal women are usually progressive and, unlike hot flashes, do not resolve spontaneously. They can have a significant impact on a woman's quality of life. These Phase 3 clinical study results indicate that this new oral tablet ha
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  A new analysis of Centers for ... enrollment data shows that 81 percent of seniors chose ... extra discounts at certain pharmacies. The findings were released ... plans are now the foundation of Medicare Part D," ...
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier ... stem cells, reported results for the second quarter of fiscal ... the Company reported revenues of $5.9 million, which compares with ... ago. Disposable revenues in the second quarter of fiscal 2011 ...
... 10, 2011 Cambrex Corporation (NYSE: CBM ) reports ... 31, 2010. Highlights ... currency, sales increased 9.2% compared to fourth quarter 2009. Adjusted ... of 54% compared to $9.4 million of EBITDA in the fourth ...
Cached Medicine Technology:ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 2ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 3ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 4ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 5ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 6ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 2Cambrex Reports Fourth Quarter and Full Year 2010 Results 3Cambrex Reports Fourth Quarter and Full Year 2010 Results 4Cambrex Reports Fourth Quarter and Full Year 2010 Results 5Cambrex Reports Fourth Quarter and Full Year 2010 Results 6Cambrex Reports Fourth Quarter and Full Year 2010 Results 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 8Cambrex Reports Fourth Quarter and Full Year 2010 Results 9
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... analytics, and clinical business intelligence solutions today announced that it is working with Oracle to further the goals of improving quality of care reporting and patient safety ... ... ... ...
... ... that builds open source platforms and develops advanced research solutions, has ... totaling more than $600,000 to focus research efforts on developing approach-specific, ... is to work towards an interactive simulator that replicates future neurosurgery ...
... BOSTON Improving on traditional screening tests for potential ... developed a laboratory technique that more closely simulates ... with the body,s normal cells. Because these neighboring ... as the "tumor microenvironment" can alter the ...
... exam, study finds , SUNDAY, March 14 (HealthDay News) -- ... and collegiate hockey players in a U.S. study had abnormal ... see if abnormal MRI results are found incidentally in active ... the department of family medicine and orthopedics at Hershey Medical ...
... below currently recommended levels did not significantly ... disease events in adults with type 2 diabetes who ... according to new results from the landmark Action to ... treating multiple blood lipids with combination drug therapy of ...
... NEW YORK, NY AND ATLANTA, GA MARCH 13, ... EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass ... compare drug-eluting stents to coronary artery bypass graft surgery ... made today at "Optimizing PCI Outcomes: Evolving Paradigms," a ...
Cached Medicine News:Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2
... The RSV ASR contains primers and a ... Respiratory Syncytial Virus (RSV). In addition, this ... probe for a,separate sample processing control. This ... FAM and Texas Red reporter dyes such ...
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Medicine Products: